Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HMGCR | P04035 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369779 | 0.85 | MAPK14 (0.48) | HTR3AMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6219428 | 0.83 | MAPK14 (0.48) | HTR3AMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6275690 | 0.83 | HTR3A (0.53) | HTR3AMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6371003 | 0.81 | HTR3A (0.53) | HTR3AMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6219192 | 0.74 | HTR3A (0.63) | HTR3AMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6219431 | 0.74 | HTR3A (0.63) | HTR3AMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6371032 | 0.74 | HTR3A (0.63) | HTR3AMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6218364 | 0.74 | HTR3A (0.81) | HTR3AMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6219132 | 0.72 | HTR3A (1.00) | HTR3AMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6218867 | 0.72 | MAPK14 (0.49) | HTR3AMAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043331-A1 | Substituted 3-(2,5-disubstituted)pyridyl-4-aryl pyrroles for treating inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043331-A1 | Substituted 3-(2,5-disubstituted)pyridyl-4-aryl pyrroles for treating inflammatory diseases | TNF, TSLP, IRAK1 | HTR3A 2032/4885MAPK14 240/4885MAPK13 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.